You are here
RESVERATROL-INSPIRED BRIDGED BICYCLIC COMPOUNDS: CHARACTERIZING A NOVEL ANTIEPILEPTIC DRUG CLASS
- Date Issued:
- 2022
- Abstract/Description:
- Epilepsy is a widely prevalent disease within the United States. It is estimated that about 1.2% of the total American population has active epilepsy, a condition of the brain that causes seizures. These seizures are marked by chemical alterations in neuronal firing that can cause abnormal behavior, sensations, muscle spasms, and loss of consciousness. Although the prevalence of seizures and epilepsy is high, effective treatments are limited and fail to provide effective treatment for nearly one-third of adult epileptic patients. Here, I conclude results of successful screening of novel compounds that can ameliorate seizures using an electroshock assay to examine seizure susceptibility and duration in C. elegans. The use of this assay provides an excellent platform for novel antiepileptic drug (AED) discovery efficiently. Literature shows Resveratrol, a natural product from plants, provides neuroprotective effects in various model organisms and therefore, is an excellent candidate for a molecule that has never been related to seizure. However, it is easily metabolized, being a flat and planar molecule. Our research group has collaboratively identified a novel bicyclic bridge molecule derived from the scaffolding of two resveratrol molecules we named Resveramorph (RVM). We also used the candidate approach to test a number of Resveramorph analogs on this assay to find the analog with highest efficacy. The various molecules characterized with their efficacy for seizure-like behavior after an electroshock have helped elucidate the mechanism of action and the RVMs physical target to give us greater insight into this potential family of AEDs.
Title: | RESVERATROL-INSPIRED BRIDGED BICYCLIC COMPOUNDS: CHARACTERIZING A NOVEL ANTIEPILEPTIC DRUG CLASS. |
27 views
12 downloads |
---|---|---|
Name(s): |
Stilley, Samantha E. , author Dawson-Scully, Kenneth, Thesis advisor Florida Atlantic University, Degree grantor Department of Biological Sciences Charles E. Schmidt College of Science |
|
Type of Resource: | text | |
Genre: | Electronic Thesis Or Dissertation | |
Date Created: | 2022 | |
Date Issued: | 2022 | |
Publisher: | Florida Atlantic University | |
Place of Publication: | Boca Raton, Fla. | |
Physical Form: | application/pdf | |
Extent: | 156 p. | |
Language(s): | English | |
Abstract/Description: | Epilepsy is a widely prevalent disease within the United States. It is estimated that about 1.2% of the total American population has active epilepsy, a condition of the brain that causes seizures. These seizures are marked by chemical alterations in neuronal firing that can cause abnormal behavior, sensations, muscle spasms, and loss of consciousness. Although the prevalence of seizures and epilepsy is high, effective treatments are limited and fail to provide effective treatment for nearly one-third of adult epileptic patients. Here, I conclude results of successful screening of novel compounds that can ameliorate seizures using an electroshock assay to examine seizure susceptibility and duration in C. elegans. The use of this assay provides an excellent platform for novel antiepileptic drug (AED) discovery efficiently. Literature shows Resveratrol, a natural product from plants, provides neuroprotective effects in various model organisms and therefore, is an excellent candidate for a molecule that has never been related to seizure. However, it is easily metabolized, being a flat and planar molecule. Our research group has collaboratively identified a novel bicyclic bridge molecule derived from the scaffolding of two resveratrol molecules we named Resveramorph (RVM). We also used the candidate approach to test a number of Resveramorph analogs on this assay to find the analog with highest efficacy. The various molecules characterized with their efficacy for seizure-like behavior after an electroshock have helped elucidate the mechanism of action and the RVMs physical target to give us greater insight into this potential family of AEDs. | |
Identifier: | FA00014072 (IID) | |
Degree granted: | Dissertation (PhD)--Florida Atlantic University, 2022. | |
Collection: | FAU Electronic Theses and Dissertations Collection | |
Note(s): | Includes bibliography. | |
Subject(s): |
Anticonvulsants Epilepsy Drug development Caenorhabditis elegans |
|
Persistent Link to This Record: | http://purl.flvc.org/fau/fd/FA00014072 | |
Use and Reproduction: | Copyright © is held by the author with permission granted to Florida Atlantic University to digitize, archive and distribute this item for non-profit research and educational purposes. Any reuse of this item in excess of fair use or other copyright exemptions requires permission of the copyright holder. | |
Use and Reproduction: | http://rightsstatements.org/vocab/InC/1.0/ | |
Host Institution: | FAU | |
Is Part of Series: | Florida Atlantic University Digital Library Collections. |